At the AUA 2024 Annual Meeting, Katie S. Murray, DO, of NYU Langone Urology and Bellevue Hospital, and Stephan Broenimann, MD, of Johns Hopkins University, highlight an evaluation of urinary comprehensive genomic profiling for non-invasive detection and molecular staging in a cohort of patients undergoing treatment for UTUC. This research, Dr. Broenimann suggests, provides evidence that urinary comprehensive genomic profiling can provide valuable diagnostic and prognostic information for the evaluation for UTUC. ...
Upper Tract Urothelial Carcinoma
Advertisement
Latest News
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Dr. Lerner shares updates from the ENLIGHTED trial and analyses pertaining to NAC for UTUC from the ROBUUST registry.
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
Padeliporfin VTP has previously shown positive safety and efficacy results for patients with low-grade UTUC.
Helen Gao highlights her comparative outcomes analysis of RNU and kidney-sparing surgery in the treatment of high-grade UTUC.
The only guideline-recommended endoluminal treatment option for patients with HG UTUC is bacillus Calmette-Guérin.
Advertisement
Urothelial Cancer Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Advertisement
Section Editor
Katie S. Murray, DOUrologic Oncologist | NYU Langone Urology and Bellevue Hospital
Advertisement
Get the latest UTUC research straight to your inbox.
